SuperVero allows Amarna to produce commercial quantities of SVac based therapeutics economically."

Our SuperVero platform

SuperVero is Amarna’s proprietary, patented producer cell line that enables the company to produce SVac vectors cheaply and in quantities sufficient for clinical and commercial use.

SuperVero consists of a genetically modified cell line derived from kidney cells of monkeys and is recommended by the World Health Organization for vaccine production for human use. SuperVero offers crucial advantages over currently used producer cell line

SuperVero benefits include:
Safe production platform
Devoid of wild type SV40
Free of infectious or virus-like particles
High production yields
Growth using serum-free culture media

Amarna’s SuperVero producer cell line has been qualified and tested using quality control assays and is available for manufacturing clinical grade recombinant SVac vector particles.

To find out more about SuperVero for biological manufacturing, please click here